Alphabet's life sciences unit halts glucose-sensing lens project
Verily, Alphabet Inc`s
The project, started in 2014, aimed to help diabetics better manage their blood sugar levels by embedding sensors on a contact lens to monitor the glucose levels in their tears.
Verily on Friday cited https://blog.verily.com/2018/11/update-on-our-smart-lens-program-with.html insufficient consistency in the correlation between tear glucose and blood glucose concentrations to support the requirements of a medical device.
Verily, which was previously part of the tech giant`s Google X research and development unit, had partnered with Novartis`
Novartis did not immediately respond to a request for comment.
Verily said it would continue to work with Alcon on two other programs, a smart accommodating contact lens for presbyopia, or far-sightedness, and a smart intraocular lens for improving sight following cataract surgery.
Verily received an $800 million investment from Singapore state investor Temasek last year.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.